Icad Jumps on Regulatory OK

iCAD ( ICAD) shares jumped Wednesday after the medical-equipment maker said the Food and Drug Administration had approved its latest breast cancer detection software.

Shares rose 72 cents, or 20.1%, to $4.19. Trading volume was three times the daily average of about 80,000 shares.

The Nashua, N.H.-based company said the FDA approved its new Second Look 200 system for early detection of breast cancer with substantially improved cancer detection software, which is designed for smaller breast care centers.

The new version can analyze up to 15 cases a day, is fully automated, fits on a counter top and is priced below $70,000.

The company said ill will market the new software system to the thousands of low-volume mammography clinics.

More from Stocks

Did Trump Just Torpedo the Stock Market Again?

Did Trump Just Torpedo the Stock Market Again?

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron